Acellular Tissue Engineered Vessel (ATEV)

Drug identity checked against registry records

Also recorded as Human Acellular Vessel (HAV)

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisNCT05908084HUMAPhase 3Active not recruiting2027-06Estimated
Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaNCT03005418HUMAPhase 2, Phase 3Completed2023-09-19Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.